The clinical pharmacology of short acting analgo-sedatives in neonates

Area of Science:

• Neonatal pharmacology
• Clinical pharmacology
• Pain management

Background:

• Effective pain management is crucial for neonatal care quality and clinical outcomes.
• Neonatal practice has evolved, necessitating updated pharmacological approaches for procedural analgo-sedation.
• Non-pharmacological therapies have advanced, but pharmacological options require re-evaluation.

Purpose of the Study:

• To review the clinical pharmacology (pharmacokinetics and pharmacodynamics) of emerging short-acting analgo-sedatives in neonates.
• To assess the suitability of agents like midazolam, propofol, remifentanil, inhalational agents, and ketamine for neonatal use.
• To identify agents with predictable disposition and limited adverse effects for neonatal procedural sedation.

Main Methods:

• Systematic assessment of pharmacodynamics (PD) and pharmacokinetics (PK) for analgo-sedation.
• Titrated administration of analgesics with subsequent re-assessment of PD.
• Review of current literature on the clinical pharmacology of specific short-acting agents in neonates.

Main Results:

• Remifentanil demonstrates predictable disposition in neonates.
• Limited pharmacodynamic side effects, including hemodynamic stability and reduced neuro-apoptosis, are associated with remifentanil.
• Other agents like midazolam, propofol, inhalational agents, and ketamine are also discussed regarding their neonatal pharmacology.

Conclusions:

• Remifentanil appears to be the most promising agent for further evaluation in neonatal analgo-sedation.
• Careful, systematic assessment and titration are essential for safe and effective neonatal analgo-sedation.
• Further research is needed to optimize the use of short-acting analgo-sedatives in neonates.